More precisely, Stubbe et al. were able to show a significant association between hypermethylated SFRP1 in cell-free DNA and poor responsiveness to gemcitabine therapy in stage IV pancreatic cancer [27]. The gene discussed is SFRP1; the disease is pancreatic neoplasm.